Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

Phase 1/2 Active not recruiting 8 enrolled Imperial College London

NaSingle-groupOpen-labelTreatment

Summary

A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation

Timeline

Start: 2019-05-08
Primary completion: 2023-04-05
Completion: 2025-10-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fostamatinib	Small molecule	150 mg	Oral

Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

Summary

Timeline

Drugs

Indications